Search results
Results from the WOW.Com Content Network
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co ...
Jo Zayner (formerly Josiah Zayner; alternatively Josie; born February 8, 1981) is a biohacker, artist, and scientist best known for their self-experimentation and work making hands-on genetic engineering accessible to a lay audience, including CRISPR.
Francisco Juan Martínez Mojica [a] (born 5 October 1963) is a Spanish molecular biologist and microbiologist at the University of Alicante in Spain.He is known for his discovery of repetitive, functional DNA sequences in bacteria which he named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats).
Doudna was introduced to CRISPR by Jillian Banfield in 2006 who had found Doudna by way of a Google search, having typed "RNAi and UC Berkeley" into her browser, and Doudna's name came up at the top of the list. [37] [38] In 2012, Doudna and her colleagues made a new discovery that reduces the time and work needed to edit genomic DNA.
Feng Zhang (Chinese: 张锋; pinyin: Zhāng Fēng; born October 22, 1981) is a Chinese–American biochemist.Zhang currently holds the James and Patricia Poitras Professorship in Neuroscience at the McGovern Institute for Brain Research and in the departments of Brain and Cognitive Sciences and Biological Engineering at the Massachusetts Institute of Technology.
In 2017, Time magazine listed him in Time 100, the list of 100 most influential people in the world. [15] [16] [17] In 2022, he was featured among the most influential people in biopharma by Fierce Pharma. [18] As of January 2023, Church serves as a member of the Bulletin of the Atomic Scientists' Board of Sponsors. [19]
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]